Study guide
5.8 OTC, Behind-the-Counter & Hazardous Drugs
Pennsylvania MPJE Pharmacy Jurisprudence Exam
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 About the PA MPJE Exam 1.2 How to Use This Study Guide
2 Federal Pharmacy Law Foundations
2.1 Controlled Substances Act & DEA Scheduling 2.2 DEA Forms, Registration & Security 2.3 Federal Food, Drug, and Cosmetic Act 2.4 HIPAA & Patient Privacy 2.5 OBRA '90, Medicare/Medicaid & DUR 2.6 DSCSA & Drug Supply Chain Integrity
3 Area 1: Licensure & Personnel (22%)
3.1 Pharmacist Licensure & the PA Board of Pharmacy 3.2 Pharmacist-in-Charge Responsibilities 3.3 Pharmacy Interns & Practical Experience 3.4 Pharmacy Technicians & Trainees (PA Registration) 3.5 License Renewal, CE & Discipline 3.6 Impaired-Pharmacist Programs & Mandatory Reporting
4 Area 2: Pharmacist Practice (33%)
4.1 Prescription Requirements & Practitioner Authority 4.2 Controlled Substance Prescribing (Federal + PA) 4.3 Refills & Authority Limitations 4.4 Drug Administration & Collaborative Practice Agreements 4.5 Patient Counseling & Documentation 4.6 Returning & Reusing Drugs 4.7 Immunizations, Naloxone & Public Health 4.8 Patient Confidentiality & Pharmacy Records
5 Area 3: Dispensing Requirements (24%)
5.1 Legitimate Medical Purpose Verification 5.2 Prescription Transfers Between Pharmacies 5.3 Prospective DUR & the PA PDMP (ABC-MAP) 5.4 Refill Exceptions & Emergency Dispensing 5.5 Labeling of Dispensed Drugs 5.6 Packaging of Dispensed Drugs 5.7 Drugs & Conditions Prohibiting Dispensing 5.8 OTC, Behind-the-Counter & Hazardous Drugs
6 Area 4: Pharmacy Operations (21%)
6.1 Ordering, Acquisition & Distribution Records 6.2 Recordkeeping, Storage & Handling 6.3 Controlled Substance Inventories 6.4 Delivery of Drugs 6.5 Product Selection & Generic Substitution 6.6 Compounding: Sterile, Nonsterile & Hazardous 6.7 Central Fill & Centralized Prescription Processing 6.8 Pharmacy Permits, Inspections & Discipline
7 Test-Day Strategy & Final Review
7.1 When PA Law Is Stricter Than Federal Law 7.2 Test-Day Strategy & Common Traps
5.8 OTC, Behind-the-Counter & Hazardous Drugs
Key Takeaways Explain This Topic AI
The Durham-Humphrey Amendment of 1951 (FDCA § 503(b)) created the modern two-tier system: legend (Rx) drugs and OTC drugs generally recognized as safe and effective (GRAS/GRASE).
The Combat Methamphetamine Epidemic Act of 2005 places pseudoephedrine and ephedrine behind the counter with a 3.6 g/day and 9 g/30-day limit per purchaser, photo ID, and a logbook.
PA does NOT require a prescription for pseudoephedrine; the federal CMEA is the controlling floor.
NIOSH hazardous drugs include antineoplastics, certain hormones, and select antivirals; USP <800> (effective Nov 2023) sets enforceable handling standards including C-PEC, C-SEC, PPE, and dedicated storage.
PA incorporates USP <800> via 49 Pa. Code §§ 27.601–27.606 (compounding rules); handling includes dispensing and counting, not just compounding.
Last updated: July 2026
Three Tiers of Drug Availability
The MPJE tests the federal scheme dividing drugs by access tier — prescription (legend), over-the-counter (OTC), and behind-the-counter (BTC) — plus PA's specific rules on pseudoephedrine and the federal scheme for NIOSH hazardous drugs. Misclassifying a product is a common error.
OTC vs Legend — The Durham-Humphrey Line
The Durham-Humphrey Amendment of 1951 (FDCA § 503(b)) created the modern two-tier system:
Tier Standard Example
Legend (Rx) "Caution: Federal law prohibits dispensing without a prescription"; unsafe for self-use Amoxicillin, atorvastatin, insulin glargine
OTC "Generally recognized as safe and effective" (GRAS/GRASE); adequate labeling for self-use Acetaminophen, ibuprofen, antacids
BTC OTC status but restricted sale at pharmacy counter Pseudoephedrine, emergency contraception in some states
A "legend drug" is one labeled with the federal Rx legend. The FDCA's prescription requirement is not waivable by a state; PA incorporates it via the Controlled Substance, Drug, Device and Cosmetic Act (35 P.S. § 780-101 et seq.) .
Behind-the-Counter — Pseudoephedrine and the Combat Methamphetamine Epidemic Act
The Combat Methamphetamine Epidemic Act of 2005 (CMEA) , incorporated at FDCA § 505(e) and 21 CFR § 1314, places all pseudoephedrine (PSE) and ephedrine products in a behind-the-counter tier:
Daily limit: 3.6 grams of PSE base per purchaser per day.
Monthly limit: 9 grams per purchaser per 30-day period.
Point of sale: Sold only at retail pharmacies or by licensed retailers; must be stored behind the counter or in a locked case; the customer may not self-select from open shelves.
Logbook: The seller must record the purchaser's name, address, date, time, and product/quantity in a bound or electronic log; the purchaser must present a photo ID.
Electronic verification: States operating NPLEx (National Precursor Log Exchange) run real-time stop-sale alerts when the monthly limit is approached.
PA has not adopted a stricter state PSE law — the federal CMEA is the floor and the controlling standard. PA does not require a prescription for PSE (unlike Oregon and Mississippi); PA's pharmacy community has supported real-time electronic stop-sale via NPLEx. On the MPJE, the answer reflecting CMEA limits (3.6 g/day, 9 g/30-day, logbook, photo ID) is correct for PA.
Emergency Contraception
Plan B One-Step and its generics are FDA-approved for OTC sale without age restriction. PA does not restrict OTC access; pharmacies may sell to any purchaser. Some states require a prescription for those under 17; PA does not.
NIOSH Hazardous Drugs and USP <800>
The National Institute for Occupational Safety and Health (NIOSH) maintains the List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings. A hazardous drug is one that can cause cancer, reproductive toxicity, organ toxicity at low doses, or genotoxicity. Common examples: chemotherapy agents (e.g., cyclophosphamide, methotrexate), certain hormones, antivirals (e.g., ribavirin).
USP General Chapter <800> (current revision effective Nov 2023) sets enforceable standards for handling hazardous drugs:
Requirement Standard
Containment Primary Engineering Control (C-PEC) Required for compounding hazardous sterile and nonsterile products
Containment Secondary Engineering Control (C-SEC) Negative-pressure room with required air exchanges
Personal protective equipment (PPE) Double chemo gloves, chemo gown, eye/face protection, respiratory protection as needed
- Receiving Wear PPE when receiving damaged or leaking hazardous drug packages
- Storage Separate negative-pressure storage area; hazard-labeled
Dispensing Wear PPE when counting, packaging, or labeling; avoid crushing; use a counting tray dedicated to hazardous drugs or a disposable tray
Waste Dispose in trace-containment bins; follow EPA and DEA as applicable
PA incorporates USP <800> via 49 Pa. Code §§ 27.601–27.606 (compounding rules). A PA pharmacy handling hazardous drugs without USP <800> controls is noncompliant.
OTC Products With Restricted Dispensing
Some OTCs are restricted in dispensing by state or federal rule:
Pseudoephedrine (CMEA, above).
Emergency contraception (Plan B) — OTC, age unrestricted.
Naloxone — under PA Act 139 of 2014 (David's Law) , pharmacists may dispense both prescription and OTC naloxone under the standing order issued by the PA Secretary of Health/Physician General (see § 5.3).
Common MPJE Traps
Treating PSE as Rx-only in PA — it is BTC, not Rx.
Failing to log a PSE sale in the pharmacy's electronic or paper log.
Stocking PSE on open shelves — a CMEA violation.
Dispensing hazardous drugs without USP <800> controls — even counting tablets counts as "handling."
Assuming PA requires a prescription for emergency contraception — it does not.
Confusing NPLEx with the PDMP — NPLEx tracks PSE; ABC-MAP tracks controlled substances.